Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.39 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.39 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099241 | 0.87 | ALDH1A1 (0.52) | KMT2AALDH1A1LMNATDP1RAB9A | |
| SCHEMBL27565532 | 0.86 | CA1 (0.43) | KMT2AALDH1A1LMNATDP1RAB9A | |
| SCHEMBL28308425 | 0.86 | ALDH1A1 (0.51) | KMT2AALDH1A1LMNATDP1RAB9A | |
| SCHEMBL3626933 | 0.80 | MAPT (0.55) | KMT2AALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL3099251 | 0.73 | ALDH1A1 (0.48) | KMT2AALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL27565531 | 0.71 | MAPT (0.47) | KMT2AALDH1A1LMNATDP1RAB9A | |
| SCHEMBL31013354 | 0.70 | RAB9A (0.48) | KMT2AALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL6885835 | 0.70 | KDM4E (0.50) | KMT2AALDH1A1LMNATDP1RAB9A | |
| SCHEMBL38666081 | 0.67 | IDE (0.65) | KMT2AALDH1A1LMNATDP1RAB9A | |
| SCHEMBL3626928 | 0.67 | IDE (0.65) | KMT2AALDH1A1LMNATDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476390-B2 | Light filters comprising P-nitrophenylazo salicylic acid derivatives thereof | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2013-07-02 | — | — | US | disclosed |
| US-20100256306-A1 | LIGHT FILTERS COMPRISING P-NITROPHENYLAZO SALICYLIC ACID DERIVATIVES THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2010-10-07 | — | — | US | disclosed |
| EP-2150588-A2 | POLYMERIC DYES BASED ON POLYMERIZABLE VINYL-GROUP CONTAINIG P-NITROPHENYL-AZO SALICYLIC ACID DERIVATIVES | Benz Research and Development Corporation (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008134555-A2 | POLYMERIC DYES BASED ON POLYMERIZABLE VINYL-GROUP CONTAINING P-NITROPHENYL-AZO SALICYLIC ACID DERIVATIVES | BENZ RESEARCH AND DEVELOPMENT CORPORATION (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256306-A1 | LIGHT FILTERS COMPRISING P-NITROPHENYLAZO SALICYLIC ACID DERIVATIVES THEREOF | UACA, SUN2, VHL | KMT2A 2076/4885ALDH1A1 356/4885LMNA 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.